KCTD21 and lung carcinoma: The results showed that more CD44-positive human lung cancer cells grew in lv-KCTD21-AS1-treated groups, but relatively fewer CD44-positive cancer cells were revealed in the siRNA-KCTD21-AS1- or miR-519d-5p-treated groups compared with the controls (Fig. 5d).